GARNIER JEAN PIERRE 4

What Happened

• Jean Pierre Garnier, a director of BioAge Labs, received a derivative award for 22,000 shares on 2026-06-10. The Form 4 reports the acquisition price as $0.00 (a grant/award rather than an open‑market purchase or sale). This is a grant of an option/award, not a sale—so it is not a liquidity event.

Key Details

• Transaction date: 2026-06-10; filing date: 2026-06-12 (filed within the standard two-business-day window).
• Security type: Derivative (option/award) for 22,000 shares; reported acquisition price $0.00.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Footnote (vesting): The entire award vests on the earlier of (i) the date of the next annual meeting or (ii) the one-year anniversary of the grant, subject to Garnier’s continued service.
• No 10b5‑1 plan, tax‑withholding sale, or late‑filing flag noted in the provided details.

Context

• This is a grant/award (often used for compensation or retention). It’s a potential future claim on shares subject to vesting conditions—does not indicate an immediate purchase or sale of stock.
• For retail investors, such grants are common for directors and are primarily compensation/retention tools; they are informational but not necessarily a direct signal of near‑term insider buying or selling.